本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

阿斯利康

75.65
-1.8500-2.39%
成交量:446.78万
成交额:3.42亿
市值:2,346.07亿
市盈率:33.62
高:76.97
开:76.11
低:75.65
收:77.50
数据加载中...

公司资料

公司名字:
阿斯利康
交易所:
NASDAQ
成立时间:
1992
员工人数:
94300
公司地址:
1 Francis Crick Avenue,Cambridge Biomedical Campus,Cambridge,Cambridgeshire,United Kingdom
邮编:
CB2 0AA
传真:
44 1223 352 858
简介:
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。

董事

名称
职位
Pascal Soriot
Executive Director and Chief Executive Officer
Aradhana Sarin
Executive Director and Chief Financial Officer
Diana Layfield
Non-Executive Director
Euan Ashley
Non-Executive Director
Karen Knudsen
Non-Executive Director
Leif Johansson
Non-Executive Chair of the Board
Marcus Wallenberg
Non-Executive Director
Michel Demare
Non-Executive Director
Nazneen Rahman
Non-Executive Director
Philip Broadley
Non-Executive Director and Non-Executive Director and Chair of Lancashire Holdings Limited
Sheri McCoy
Non-Executive Director
Tony Mok
Non-Executive Director

股东

名称
职位
Marc Dunoyer
Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca
Pascal Soriot
Executive Director and Chief Executive Officer
Aradhana Sarin
Executive Director and Chief Financial Officer
David Fredrickson
Executive Vice-President, Oncology Business Unit
Iskra Reic
Executive Vice-President, Vaccines, Executive Vice President and Immune Therapies
Jeff Pott
Chief Compliance Officer, Chief Human Resources Officer and General Counsel
Katarina Ageborg
Executive Vice-President, Sustainability and Chief Compliance Officer, President of AstraZeneca AB Sweden
Leon Wang
Executive Vice-President, International and China President
Menelas Pangalos
Executive Vice-President, BioPharmaceuticals R&D
Pam Cheng
Executive Vice-President, Operations, Information Technology and Sustainability
Ruud Dobber
Executive Vice-President and President, BioPharma ceuticals Business Unit
Susan Galbraith
Executive Vice-President, Oncology R&D